General pathologist specializing in urologic path (tweets #gupath ). Trustee of American Board of Pathology. Also love music, sports, my wife and two boys.
A lot of residents and students want to know what a day in the life of a private practice pathologist is like: Here's my day
730-8: Arrive and get logged in. Today was a password change day. Had to fix a lot of stuff with email program, Epic, phone, etc.
1/10
Join our upcoming MiSP meeting! đŹConnect, share ideas, and discuss the latest in pathology.
Saturday December 6, 2025
The Henry, Autograph Collection | Dearborn, Michigan
Register now to be part of the conversation!
wjweis.association-service.oâŚ
Our October newsletter is in đđ
Read here: linktr.ee/MichiganSocietyofPâŚ
Receive more updates & news by signing up here: shorturl.at/D1yIE
Shout out to the medical student/ trainee forum for their efforts to curate this special edition!
#MiSP2025
Thinking about a future in pathology?đŹ
Tune in to our panel discussion top learn more!
Save the date đŁ
Thursday Oct 9, 2025
6pm ET
Register: umich.zoom.us/webinar/registâŚ
Comments are helpful - there has been lots of discussion on what topics are appropriate for general AP/CP boards and what topics are "fellowship level" - please look through and comment (easy to do by means of a survey-type response that can be found at the link)
The draft Content Specifications for certification exams are open for public review. Residents & fellows may use them as general study guides as they prepare for exams. Please note-the drafts are not final and may be updated following feedback. #pathboardsbit.ly/3CeFzLs
The draft Content Specifications for certification exams are open for public review. Residents & fellows may use them as general study guides as they prepare for exams. Please note-the drafts are not final and may be updated following feedback. #pathboardsbit.ly/3CeFzLs
#GUpath prostate biopsy:
controversies in applying volume of core involved:
â95% of core involved by prostate cancer?
đ
â15% of core, discontinuously involved
there's data on both sides...so use your judgement and explain how you arrived at your reporting!
if youâre seeing PSA level â97.20 ng/mlâ somewhere on pros bx path report, its likely wrong
97.20 is the ICD code for elevated PSA
Iâve seen this error often! Mistake gets passed along patient chart! May not be a false neg bx that didnât correlate!
example heređđ˝
Agree, no need for total submission. In our lab we routinely have partially submitted for years, and our rates of detecting T3 disease are probably higher than most. A good PA or grosser helps, as does correlation with bx/imaging. Low threshold to go back and submit more. #gupath
Why is prostate sampling so unique? Radical prostatectomies are the only resection specimens routinely submitted in total for histological examination with significant workload implications for pathologists and laboratories. Is this really necessary?
đ¨Excited to share publication of the G-MINOR trial today in @EUplatinum. This cluster-crossover trial enrolled 338 patients at high risk of local recurrence post-RP and randomized them to /- genomic testing (Decipher). G-MINOR Trial on genomic classifier testing (Decipher)đ§Ź
I'm thrilled to be able to share this report from the symposium CAncer or Not Cancer?: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?), out today @JNCI_Now
When is prostate cancer really cancer? academic.oup.com/jnci/articlâŚ
After 4 years of the GĂTEBORG-2 trial, MRI-targeted biopsy led to less detection of clinically insignificant prostate cancer than systematic biopsy without compromising the detection of cancer that may affect survival. Read the full trial results: nej.md/4ewOjKT
ALT Graphs of the cumulative incidence of detection of clinically insignificant prostate cancer, clinically significant prostate cancer, and advanced or high-risk prostate cancer.
If anyone else uses the LLM AI apps, I'm getting a bit frustrated with them. I asked it a simple question about a great 1990s movie and it had no idea what it was talking about g.co/gemini/share/899a930c47âŚ
We are delighted to announce the election of Dylan Miller, MD, to the ABPath Board of Trustees, effective January 1, 2025. Dr. Miller's extensive expertise and experience will be invaluable to the Board. Please join us in welcoming Dr. Miller! #pathologyabpath.org/2024/08/abpath-weâŚ
We are saddened to hear of the recent passing of former ABPath Trustee William W. McLendon, MD. His legacy in Pathology, Laboratory Medicine and leadership will continue to inspire us. More on his life and contributions on the ABPath website: bit.ly/4cg9ajV.
"As you grow older, it becomes okay to say, âI donât know.â People donât like ambiguity when they are younger; they want everything in black and white. But many things about pathology (and life!) are ambiguous. There are always shades of grey."
thepathologist.com/outside-tâŚ